EDARBI® (azilsartan medoxomil) is a prescription medicine called an angiotensin II receptor blocker (ARB) used to treat high blood pressure (hypertension) in adults. Your doctor may prescribe other medicines for you to take along with EDARBI to treat your high blood pressure.

Market Analysis and Insights: Global Edarbi Market
The global Edarbi market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Edarbi Scope and Market Size
The global Edarbi market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Edarbi market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
20mg
40mg
80mg

Segment by Application
Hospital
Drug Store
On-Line

The Edarbi market is analysed and market size information is provided by regions (countries). Segment by Application, the Edarbi market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Takeda
Arbor Pharmaceuticals